A large cohort study in patients with type 2 diabetes found no increased risk of suicidality among those receiving glucagon-like peptide-1 receptor agonists compared with dipeptidyl peptidase-4 inhibitors or sodium-glucose cotransporter-2 inhibitors. The study initially suggested increased suicidality with GLP-1 receptor agonists, but after adjusting for confounders, the association was null. Similar findings were observed when comparing GLP-1 receptor agonists with SGLT-2 inhibitors. The researchers concluded that GLP-1 receptor agonists do not increase the risk of suicidality among patients with type 2 diabetes.

Source: The BMJ